Rockwell Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.18 Mil. Rockwell Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.26 Mil. Rockwell Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $21.29 Mil.
Rockwell Medical's debt to equity for the quarter that ended in Dec. 2023 was 0.63.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rockwell Medical's Debt-to-Equity or its related term are showing as below:
RMTI'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2 Med: 0.7 Max: 11.4
Current: 0.63
During the past 13 years, the highest Debt-to-Equity Ratio of Rockwell Medical was 11.40. The lowest was 0.20. And the median was 0.70.
Rockwell Medical Debt-to-Equity Historical Data
The historical data trend for Rockwell Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Rockwell Medical Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
0.20 |
0.70 |
11.40 |
1.16 |
0.63 |
|
Rockwell Medical Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.16 |
1.23 |
1.68 |
0.69 |
0.63 |
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical Debt-to-Equity Distribution
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Debt-to-Equity falls into.
Rockwell Medical Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Rockwell Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Rockwell Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (Rockwell Medical) Business Description
Traded in Other Exchanges
Address
30142 S. Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. Rockwell Medical's mission is to provide dialysis clinics and patients with the highest quality products supported by the best customer service in the industry. It is focused on innovative, long-term growth strategies that enhance products, processes, and people, enabling the company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients.
Executives
| Jesse Neri |
officer: SVP, FINANCE |
851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087 |
| Joan Lau |
director |
C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
| Russell Skibsted |
officer: See Remarks |
15 TRANQUILITY PLACE, LADERA RANCH CA 92694 |
| Megan C. Timmins |
officer: SVP, General Counsel |
600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
| Mark Strobeck |
director, officer: President and CEO |
460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087 |
| Allen Nissenson |
director |
601 HAWAII ST., EL SEGUNDO CA 90245 |
| Robert S Radie |
director |
101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
| Andrea Heslin Smiley |
director |
600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
| David S. Richmond |
10 percent owner, other: See Footnote 1 |
3568 WILDWOOD AVENUE, JACKSON MI 49202 |
| Russell H Ellison |
director |
270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025 |
| Marc L Hoffman |
officer: Chief Medical Officer |
30142 WIXOM ROAD, WIXOM MI 48393 |
| John Peter Mclaughlin |
director |
C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451 |
| Richmond Brothers, Inc. |
10 percent owner, other: See Footnote 1 |
7415 FOXWORTH COURT, JACKSON MI 49201 |
| Stuart M Paul |
director, officer: Chief Executive Officer |
HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309 |
| Angus W. Smith |
officer: Chief Financial Officer |
C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960 |
Rockwell Medical (Rockwell Medical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RMTI has been successfully added to your